Control and Treatment of Outpatient Children With Asthma
ConditionAsthma
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age2-18
SponsorBeijing Children's Hospital
About this trial
The aim of this study is to comprehensively understand the disease control and management status of children with asthma in China, as well as the types of airway inflammation. The findings of this survey will help improve the asthma control level in Chinese children, facilitate future patient education, and guide rational medication use. Moreover, it will provide important evidence for health decision-making departments to better allocate and utilize medical resources.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Age between 2 and 18 years old
Diagnosed with asthma for more than 3 months
Had asthma symptoms or asthma treatment within the past 12 months.
Disqualifiers
With other respiratory diseases such as bronchiectasis, bronchiolitis, cystic fibrosis, and pneumonia
Have participated in any interventional clinical studies related to asthma within the 3 months prior to enrollment in this study
Parents, legal representatives, or guardians do not agree to participate in this study.
Trial population
Children aged 2-18 years and diagnosed with asthma ≥3 months were enrolled in the study.
Trial design
Design model
Cohort
Time perspective
Cross-sectional
Treatments tested in this trial
Questionnaire and Physical Exam
Other interventionQuestionnaire and Physical Exam
Treatment groups
No treatment groups listed
Trial outcomes
Primary outcomes
1
Asthma control level
The Asthma Control Test (ACT) will be employed for assessment, with the following interpretation criteria: a total score of 20-25 indicates well-controlled asthma, where symptoms are satisfactorily managed and the current treatment regimen should be continued; a score of 16-19 suggests poorly controlled asthma, indicating suboptimal symptom management that requires treatment adjustment or enhanced disease management; and a score of 5-15 reflects very poorly controlled asthma, with severe uncontrolled symptoms necessitating immediate medical attention and treatment modification.
Time frame
3 months before and at the time of enrollment2
The proportion of type 2 inflammation
Blood EOS and IgE were used to judge. The T2 inflammatory phenotypes were classified based on blood eosinophil count and total specific IgE levels: Only-atopy was defined as blood eosinophils \<300/μL with sum of all specific IgE ≥0.7 kU/L; Only-EOS as blood eosinophils ≥300/μL with sum of all specific IgE \<0.7 kU/L; T2-high as blood eosinophils ≥300/μL with sum of all specific IgE ≥0.7 kU/L; and T2-low as blood eosinophils \<300/μL with sum of all specific IgE \<0.7 kU/L.
Time frame
3 months before and at the time of enrollmentLocations
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Beijing Children's Hospital
Lead sponsor
Shenzhen Children's Hospital
Sponsor institution
Source ClinicalTrials.gov
This trial is not recruiting at the moment. You can still explore other options: